Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 92

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 92
---

We earned interest income on our cash balances and investments in U.S. Treasury bills.

18

Results of Operations

The following tables summarize our results of operations for the three and nine months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeOperating expenses:Research and development$1,553 $2,151 $(598)$5,283 $8,529 $(3,246)General and administrative1,180 1,419 (239)3,549 4,853 (1,304)Total operating expenses2,733 3,570 (837)8,832 13,382 (4,550)Loss from operations(2,733)(3,570)837 (8,832)(13,382)4,550 Interest income59 48 11 92 286 (194)Other income, net3 9 (6)185 9 176 Net loss$(2,671)$(3,513)$842 $(8,555)$(13,087)$4,532 

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $53 $(53)$— $114 $(114)INVINCIBLE-2 Study (Phase 2 Breast)— 12 (12)— 233 (233)INVINCIBLE-3 Study (Phase 3 Sarcoma)883 1,225 (342)3,267 4,613 (1,346)INVINCIBLE-4 Study (Phase 2 Breast)126 108 18 323 424 (101)Other— — — 14 58 (44)Clinical trial expenses1,009 1,398 (389)3,604 5,442 (1,838)Contract manufacturing30 20 10 59 651 (592)Salaries and benefits related costs303 497 (194)925 1,340 (415)Consulting & Other29 49 (20)90 126 (36)Stock-based compensation182 187 (5)605 970